UBS Group set a €108.00 ($125.58) price target on Merck KGaA (FRA:MRK) in a research report released on Monday, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
A number of other research firms have also recently commented on MRK. Societe Generale set a €105.00 ($122.09) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Wednesday, March 27th. Warburg Research set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Wednesday, March 27th. DZ Bank restated a neutral rating on shares of Merck KGaA in a report on Tuesday, March 19th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the company a buy rating in a research note on Tuesday, March 19th. Finally, Kepler Capital Markets set a €110.00 ($127.91) price objective on shares of Merck KGaA and gave the company a buy rating in a research note on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of Hold and an average price target of €100.65 ($117.03).
MRK opened at €101.30 ($117.79) on Monday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
See Also: Float
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.